Ecrins Therapeutics

Ecrins Therapeutics aims to develop ET-D5 for the treatment of cancer in dogs, and to put this new therapy on the market. For this, Ecrins Therapeutics launched two projects: In 2010, Ecrins Therapeutics won the EUREKA transnational grant for the CADAC (Canine Antivascular Drug Against Cancer) project. The CADAC's objective is to test ET-D5 in a cl... inical trial in dogs with spontaneous cancers. For this, Ecrins Therapeutics works together with two experienced partners: AOIC (Animal Oncology and Imaging Center), based in Switzerland, and VRCC (Veterinary Referrals Cancer and critical care Centre limited), based in United Kingdom. AOIC and VCCR are leading animal oncology centers - highly experienced in diagnosing and treating canine cancer patients as well as testing new therapeutic approaches in experimental settings. For the project Dog-To-Man, Ecrins Therapeutics teamed together with two academics partners (CLB - Lyon, and IGDR - Rennes), and one private veterinary clinic (ORC - Lille), in order to evaluate the efficacy of ET-D5 in canine sarcomas (see news). The project represents a classic case of translational research, meaning that we have two goals: to identify a new treatment for canine sarcomas, and to use the obtained knowledge to guide the treatment of human patients suffering from sarcomas. This approach is particularly attractive since (like many other cancers) sarcomas in dogs and humans share many similarities.Read More